• Piotr Desperak, Bartosz Hudzik, and Mariusz Gąsior.
• 3rd Department of Cardiology, Silesian Centre for Heart Diseases in Zabrze, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland
• Pol. Arch. Med. Wewn. 2019 Aug 29; 129 (7-8): 460-468.

IntroductionThe positive outcomes of the COMPASS trial raise questions about the proportion of patients who could benefit from additional therapy with rivaroxaban in real‑world practice.ObjectivesWe aimed to identify the proportion of patients from the TERCET registry with significant coronary artery disease (TERCET‑CAD) who could benefit from the use of rivaroxaban and to assess their clinical characteristics and long‑term prognosis in comparison with the corresponding measures in the COMPASS trial.Patients And MethodsThe COMPASS criteria were applied in the TERCET‑CAD population. Patients who met the criteria of the COMPASS trial were included in the COMPASS‑like group. The baseline characteristics and long‑term outcomes of the COMPASS‑like group were compared with the corresponding measures in the acetylsalicylic acid (ASA)-alone arm from the COMPASS trial.ResultsThe COMPASS‑like group included 3884 patients (31.6%) out of the 12 286 patients constituting the TERCET‑CAD population. Patients in the COMPASS‑like group were characterized by older age (P <0.001) and a more frequent occurrence of risk factors for CAD than those in the ASA‑alone arm of the COMPASS trial. The rate of a composite endpoint in the COMPASS‑like group was 9%, and in the ASA‑alone arm of the COMPASS trial, it was 6% (P <0.001).ConclusionsLess than one-third of the TERCET‑CAD population met the COMPASS criteria and could potentially benefit from low‑dose rivaroxaban therapy. Unfavorable clinical profiles and higher rates of adverse events in the TERCET registry compared with those in the COMPASS trial may predict greater benefits from the implementation of low‑dose rivaroxaban in the real‑world population.

17 keywords...

hide…